Lufepirsen

DB14915Investigational

CODA-001 is under investigation in clinical trial NCT01165450 (Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects).

Mechanism: Pharmacologically active on Gap junction alpha-1 protein
Curator reviewed
Also known as: NEXAGON
Code names: CODA-001

Resolves to

Compound

Targets

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lufepirsen, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.